ARTICLE | Company News
Isarna Therapeutics, Autotelic deal
November 16, 2015 8:00 AM UTC
Autotelic purchased worldwide rights to Isarna’s trabedersen, an antisense oligonucleotide targeting transforming growth factor (TGF) beta 2 (TGFB2). The product was in Phase III testing to treat rec...